EpidStrategies, A Division of ToxStrategies, Inc, Rockville, Maryland, USA.
Sanofi, Swiftwater, Pennsylvania, USA.
J Infect Dis. 2022 Aug 15;226(Suppl 2):S267-S281. doi: 10.1093/infdis/jiac226.
A systematic literature review was conducted to summarize the mortality (overall and by disease severity factors) of US infants and children aged <5 years with respiratory syncytial virus (RSV) or all-cause bronchiolitis (ACB).
Comprehensive, systematic literature searches were conducted; articles were screened using prespecified eligibility criteria. A standard risk of bias tool was used to evaluate studies. Mortality was extracted as the rate per 100 000 or the case fatality ratio (CFR; proportion of deaths among RSV/ACB cases).
Among 42 included studies, 36 evaluated inpatient deaths; 10 used nationally representative populations updated through 2013, and only 2 included late-preterm/full-term otherwise healthy infants and children. The RSV/ACB definition varied across studies (multiple International Classification of Diseases [ICD] codes; laboratory confirmation); no study reported systematic testing for RSV. No studies reported RSV mortality rates, while 3 studies provided ACB mortality rates (0.57-9.4 per 100 000). CFRs ranged from 0% to 1.7% for RSV (n = 15) and from 0% to 0.17% for ACB (n = 6); higher CFRs were reported among premature, intensive care unit-admitted, and publicly insured infants and children.
RSV mortality reported among US infants and children is variable. Current, nationally representative estimates are needed for otherwise healthy, late-preterm to full-term infants and children.
系统综述旨在总结美国 5 岁以下因呼吸道合胞病毒(RSV)或所有病因毛细支气管炎(ACB)住院的婴儿和儿童的死亡率(整体和按疾病严重程度因素)。
进行了全面、系统的文献检索;使用预先确定的纳入标准筛选文章。使用标准的偏倚风险工具评估研究。死亡率以每 10 万例的比率或病死率(RSV/ACB 病例中的死亡比例)提取。
在 42 项纳入的研究中,36 项评估了住院患者的死亡情况;10 项研究使用了截至 2013 年更新的全国代表性人群,只有 2 项研究纳入了晚期早产儿/足月儿且健康的婴儿和儿童。RSV/ACB 的定义在研究中各不相同(多个国际疾病分类[ICD]代码;实验室确认);没有研究报告系统地检测 RSV。没有研究报告 RSV 死亡率,而 3 项研究提供了 ACB 死亡率(每 10 万例 0.57-9.4 例)。RSV(n=15)的病死率范围为 0%至 1.7%,ACB(n=6)的病死率范围为 0%至 0.17%;早产儿、入住重症监护病房和有公共保险的婴儿和儿童的病死率较高。
美国婴儿和儿童报告的 RSV 死亡率各不相同。目前需要针对健康的晚期早产儿至足月儿婴儿和儿童进行全国代表性的估计。